Search Within

Mikhail Roshal

Formats
  1. Meeting Abstract (109)
  2. Journal Article (82)
  3. Book Section (15)
  4. Research Letter (11)
  5. Review (9)
  6. Correspondence (1)
  7. Editorial (1)
  8. Guidelines (1)
Groups
  1. Department of Pathology and Laboratory Medicine (229)
  2. Center for Hematologic Malignancies (151)
  3. Department of Medicine (143)
  4. Hematologic Malignancies, Division of (142)
  5. Adult Leukemia (98)
  6. Sloan Kettering Institute Postdocs (73)

More Groups

People
  1. Ahmet Dogan (95)
  2. Maria Arcila (68)
  3. Qi Gao (64)
  4. Wenbin Xiao (63)
  5. Yanming Zhang (58)
  6. Sergio Giralt (39)

More People

Years
  1. 2025 (8)
  2. 2024 (9)
  3. 2023 (26)
  4. 2022 (23)
  5. 2021 (27)
  6. 2020 (26)

More Years

Publications
  1. Blood (63)
  2. Laboratory Investigation (23)
  3. Modern Pathology (18)
  4. Blood Advances (15)
  5. Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. 3rd ed (14)
  6. Cytometry Part B—Clinical Cytometry (7)

More Publications

Publishers
  1. American Society of Hematology (78)
  2. Nature Publishing Group (29)
  3. Elsevier Inc. (24)
  4. Nature Research (19)
  5. Wiley Blackwell (13)
  6. Elsevier Science, Inc. (8)

More Publishers

Results (229)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma
    Journal Article

    Rustad, E. H.; Hultcrantz, M.; Yellapantula, V. D.; Akhlaghi, T.; Ho, C.; Arcila, M. E.; Roshal, M.; Patel, A.; Chen, D.; Devlin, S. M.; more...
    PLoS ONE (2019)

    Fulltext@MSK | Save
  • Establishment of immunoglobulin heavy (IGH) chain clonality testing by next-generation sequencing for routine characterization of B-cell and plasma cell neoplasms
    Journal Article

    Arcila, M. E.; Yu, W.; Syed, M.; Kim, H.; Maciag, L.; Yao, J.; Ho, C.; Petrova, K.; Moung, C.; Salazar, P.; more...
    Journal of Molecular Diagnostics (2019)

    Fulltext@MSK | Save
  • Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation
    Journal Article

    Xiao, W.; Yabe, M.; Offin, M.; Khattar, P.; Baik, J.; Daley, R. J.; Pappacena, J. J.; Roshal, M.; Zhang, Y.; Tallman, M. S.; more...
    Blood Advances (2018)

    Fulltext@MSK | Save
  • PHF6 mutations are mutually exclusive to TP53 mutations, and define a distinct subgroup of secondary acute myeloid leukemia associated with a primitive stem/progenitor immunophenotype, absent complex karyotype and relatively better outcomes
    Meeting Abstract

    Xiao, W.; Goldberg, A. D.; Ball, B.; Famulare, C.; Pastore, F.; Tallman, M. S.; Zhang, Y.; Arcila, M. E.; Papaemmanuil, E.; Levine, R. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Loss of plasmacytoid dendritic cell differentiation is highly predictive for persistent measurable residual disease and poor outcomes in acute myeloid leukemia
    Meeting Abstract

    Xiao, W.; Goldberg, A. D.; Famulare, C.; Delvin, S.; Patel, M.; McGovern, E.; Patel, A.; Schulman, J.; Dunbar, A.; Epstein-Peterson, Z. D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions
    Meeting Abstract

    Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Mims, A. S.; Pratz, K. W.; Savona, M. R.; Stein, A. S.; Stone, R. M.; Winer, E. S.; Seet, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
    Meeting Abstract

    Korde, N.; Mastey, D.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Tavitian, E.; Salcedo, M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Molecular predictors and current management of minimal residual disease (MRD) following induction chemotherapy for acute myeloid leukemia (AML)
    Meeting Abstract

    Goldberg, A. D.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Menghrajani, K.; Patel, M.; Cai, S.; Dunbar, A.; Epstein-Peterson, Z. D.; McGovern, E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • V(D)J sequence capture for DNA-based minimal residual disease detection in multiple myeloma
    Meeting Abstract

    Rustad, E. H.; Hultcrantz, M.; Yellapantula, V. D.; Akhlaghi, T.; Ho, C.; Arcila, M. E.; Roshal, M.; Patel, A.; Devlin, S. M.; Jacobsen, A.; more...
    Blood (2018)

    Fulltext@MSK | Save